Grufity logo
Grufity logo
TRVN

TRVN - Trevena Inc Stock Price, Fair Value and News

00
Market Closed as of 15 Jun 2026, 04:00 pm ET

81/100

TRVN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

81/100

TRVN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

TRVN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TRVN Price Action

Last 7 days

-100%

Last 30 days

-100%

Last 90 days

-100%

Trailing 12 Months

-100%

TRVN RSI Chart

TRVN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TRVN Valuation

Market Cap

8.5K

Price/Earnings (Trailing)

-3e-4

Price/Sales (Trailing)

0.02

EV/EBITDA

-0.18

Price/Free Cashflow

-3e-4

TRVN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

TRVN Fundamentals

TRVN Revenue

TRVN Earnings

TRVN Profitability

Free Cashflow Yield

-317.4K%

TRVN Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2022----
20213.3M3.5M637.0K567.0K
20204.7M4.1M3.6M3.1M
2019---5.2M
2018-4.4M5.5M5.7M
20167.5M7.5M5.6M3.8M
2015718.8K2.5M4.4M6.3M
2013639.4K471.3K303.1K135.0K
2012---807.6K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Trevena Inc

TRVN
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.
 CEO
 WEBSITEtrevena.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES35

Trevena Inc Frequently Asked Questions

TRVN is the stock ticker symbol of Trevena Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jun 12 2026, market cap of Trevena Inc is 8.55 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jun 12 2026, TRVN's PE ratio (Price to Earnings) is 0 and Price to Sales (PS) ratio is 0.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TRVN PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Trevena Inc has provided -1 (multiply by 100 for percentage) rate of return.